Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertelli, G.
Right arrow Articles by Rosso, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertelli, G.
Right arrow Articles by Rosso, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:883-888, 2002
© 2002 European Society for Medical Oncology

Original Paper

Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study

G. Bertelli1,+, M. Venturini2, L. Del Mastro2, M. Bergaglio2, P. Sismondi3, N. Biglia3, S. Venturini4, G. Porcile5, P. Pronzato6, M. Costantini2 and R. Rosso2

1Medical Oncology, S.Croce General Hospital, Cuneo; 2National Cancer Institute, Genova; 3Gynecological Oncology, University of Torino, Torino; 4Medical Oncology, City Hospital, Massa; 5Medical Oncology, City Hospital, Alba; 6Medical Oncology, S. Andrea Hospital, La Spezia, Italy

Received 2 July 2001; revised 15 October 2001; accepted 14 December 2001.

Background

Hot flashes are frequent in postmenopausal breast cancer patients, especially when treated with tamoxifen. Estrogen replacement therapy is the most effective treatment for hot flashes, but its use is controversial in breast cancer survivors. Progestins may offer a good alternative for the control of hot flashes in this setting; in particular, oral megestrol acetate has been proven effective in a randomized, placebo-controlled clinical trial. With the aim of further improving these results, we have designed a randomized study comparing oral megestrol acetate with depot intramuscular (i.m.) medroxyprogesterone acetate (MPA) for the control of hot flashes in postmenopausal patients with a history of breast cancer.

Patients and methods

Seventy-one postmenopausal patients were randomized to receive an i.m. injection of depot MPA 500 mg on days 1, 14 and 28, or oral megestrol acetate 40 mg daily for 6 weeks. Patients recorded daily the number and severity of their hot flashes; response was defined as a >=50% decrease in the number and severity of hot flashes.

Results

At week 6, hot flashes were reduced by 86% on average in the whole group of patients, without significant differences between the two progestins. Response was obtained by 75 and 67% of patients receiving MPA or megestrol, respectively (P = 0.5). Responders were followed to assess maintenance of response (without further treatment), which was significantly better with i.m. MPA: in this group, 89% of responders still showed a benefit at week 24, compared with 45% in the megestrol group (P = 0.03).

Conclusions

Our study shows that a short cycle of i.m. depot MPA injections provides significant and long-lasting relief from postmenopausal hot flashes in patients with a history of breast cancer, offering an alternative to estrogen replacement therapy or prolonged administration of oral megestrol.

Key words: breast cancer, hot flashes, medroxyprogesterone acetate, megestrol acetate, postmenopausal symptoms, tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. H. Boekhout, J. H. Beijnen, and J. H.M. Schellens
Symptoms and treatment in cancer therapy-induced early menopause.
Oncologist, June 1, 2006; 11(6): 641 - 654.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Loprinzi, R. Levitt, D. Barton, J. A. Sloan, S. R. Dakhil, D. A. Nikcevich, J. D. Bearden III, J. A. Mailliard, L. K. Tschetter, T. R. Fitch, et al.
Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7
J. Clin. Oncol., March 20, 2006; 24(9): 1409 - 1414.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.